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EDITORIAL
The Seventh Tumor, Node, Metastasis Staging System and
Lung Cancer Treatment Choices
A Matter of Would, Could, and Should
Johan F. Vansteenkiste, MD, PhD,* and Frances A. Shepherd, MD, PhD†
The Seventh edition of the tumor, node, metastasis (TNM) classification of lungneoplasms (TNM7) has been in use since January 1, 2010. This is the result of the
hitherto unprecedented work of the International Staging Committee of the International
Association for the Study of Lung Cancer (IASLC) led by Mr. Peter Goldstraw.1 Based
on more than 100,000 case records, changes to TNM6 were proposed and validated. The
effort was rewarded by adoption of the new classification by both the American Joint
Committee on Cancer and the Union Internationale Contre le Cancer and resulted in a
“seismic shift in lung cancer staging.”2 Most of the changes were in the T category3; the
M1 category was adapted to M1a and M1b,4 whereas there were essentially no changes
in the N categories.5
In this issue of Journal of Thoracic Oncology, Boffa et al.6 report on a study they
performed to evaluate how much clinicians feel that a change in stage should lead to a
change in management for a given patient. At four lung cancer symposia, clinicians were
asked to give their preferred treatment strategy for three hypothetical case records. First,
they were presented with each patient’s TNM6 stage and then with the new TNM7 stage
designation. Not less than 77% of the respondents changed treatment intention in at least
one case, despite the fact that the changes made to the lung cancer staging system as a
result of the IASLC analyses were not based on treatment administered. Because of this,
altering the treatment decisions based on upstaging or downstaging of a case is not really
justified at this time.
This article has limitations: a major one is the low number of surveyed clinicians
and the low response rate (on average only 32% across the four meetings). Furthermore,
the attendance to these meetings was quite heterogeneous, and no information on
participants and their background or expertise was provided. It is nonetheless of interest
because it is the first one to show that clinicians would change their treatment because of
the TNM7 classification change. The article does raise the point that a change in TNM
staging could potentially lead to changes in treatment, even if on theoretical grounds this
should not be the case.
In his editorial to the IASLC proposal in 2007, Dr. Silvestri previously pointed out
that—apart from providing an anatomic description of the cancer to have groupings with
similar prognosis—perhaps the most important rationale for staging is that stage dictates
treatment and that treatment regimens vary considerably by stage.2 Indeed, most stage I
cases in the IASLC database had a good prognosis because they had surgical resection (or
radical radiotherapy if medically inoperable), illustrating the unavoidable link between
any staging system and treatment.
So, how do we deal with this issue of would, could, and should? One theoretical
option is to stage according to TNM7 and temporarily look in terms of TNM6 for
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treatment decisions, but this would become a nightmare for
clinicians. To assess the impact of treatment (particularly in
the postoperative adjuvant setting), individual hospital data-
bases could be analyzed with outcomes plotted according to
both TNM6 and TNM7. However, this approach may be
suboptimal because treatment will not be homogeneous and
data may not be complete. Furthermore, since 2004, in the
nonrandomized setting, most fit patients will receive adjuvant
therapy and so there will be no untreated control arm; finally,
the outcome of untreated patients may be influenced more by
prognostic factors that made them unfit for chemotherapy
than by the absence of postoperative treatment. A better
solution might be to reanalyze previous adjuvant clinical trial
data acquired with TNM6 according to the new TNM7. Stage
shifts due to the T factor from TNM6 to TNM7 are related to
three main components: the size of the primary tumor (e.g.,
7 cm now T3 instead of T2), the location of an additional
nodule (e.g., same lobe now T3 instead of T4), or the local
invasiveness of the tumor in the absence of mediastinal
lymph node metastases (e.g., sulcus superior now stage IIIA
and no longer IIIB).3 A reanalysis of the individual patient
data-based lung adjuvant cisplatin evaluation (LACE) meta-
analysis on adjuvant platin-based chemotherapy is currently
ongoing.7 However, sufficient details on the T-factor—in-
cluding maximum diameter—is only available for two of the
trials in the LACE database, and so the analyses may have
limited power to detect significant benefit or interaction based on
the new T descriptors.8,9 This information hopefully will become
available from large ongoing adjuvant studies, such as the
MAGRIT study (MAGE-A3 as adjuvant non-small cell lung
cancer immunotherapy, NCT00480025), with MAGE-A3
cancer immunotherapy,10 where all the details of the T-factor
are registered prospectively.
In the meantime, how should clinicians balance between
theoretical principles and clinical realities? It is not a coinci-
dence that all three components mentioned above were already
areas of discussion in the era of TNM6. In respect to size of the
primary tumor, LACE confirmed the role of adjuvant chemo-
therapy for stages II and IIIA, whereas the effect in stage IB was
beneficial but not significant (hazard ratio [HR]  0.93; 95%
confidence interval [CI]  0.78–1.10).7 In the only study that
addressed adjuvant chemotherapy specifically in stage IB, the
overall result again pointed to better but not significantly differ-
ent survival (HR  0.83; 95% CI  0.64–1.08), but patients
with tumors 4 cm had a significant survival benefit with
adjuvant therapy in a subanalysis (HR  0.69; 95% CI 
0.48–0.99).11 Interestingly, this cutpoint of 4 cm was totally
arbitrary and conformed neither to T subgroups of TNM6 nor
TNM7! Although the data were thus insufficient for an overall
recommendation of adjuvant therapy in stage IB, some groups
felt that patients with larger primary tumors might benefit,12 and
these patients (with a tumor5 cm) now move from stage IB to
II. Similarly, most clinicians will agree that operable patients
with one additional nodule in the same lobe deserve a lobec-
tomy, again a treatment more in line with the current stage IIIA
than the previous stage IIIB setting.13 Finally, recent papers on
patients with a superior sulcus tumor without mediastinal nodes
report favorable outcomes with surgical multimodality treat-
ment, again closer to current stage IIIA than the previous stage
IIIB staging.14 How clinicians and treatment guideline groups
will find the best way to deal with this difficult balance will most
probably remain a matter of debate and consensus, until the
large-scale prospective clinical trial data acquired in the TNM7
era become available from clinical trials and from the IASLC
prospective staging initiative.
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